Immunoglobulin G molecules, key mediators of immune protection and burgeoning therapeutic reagents, exist in different forms or subclasses. In her Perspective, [Woof][1] discusses new work by [Nimmerjahn and Ravetch][2] that reveals how, in some settings, the in vivo functional capabilities of each subclass may be predicted on the basis of differential interaction with specific cellular Fc receptors. [1]: http://www.sciencemag.org/cgi/content/full/310/5753/1442 [2]: http://www.sciencemag.org/cgi/content/full/310/5753/1510
No takes yet. Share an insight, caveat, or question.
Jenny M. Woof (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: